The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer’s disease treatment?

Power Calculations for Clinical Trials in Alzheimer's Disease

(2018) M. Colin Ard et al.   JOURNAL OF ALZHEIMERS DISEASE

Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?

(2017) Robert E. Becker et al.   JOURNAL OF ALZHEIMERS DISEASE

Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data

(2016) Erin L. Ashbeck et al.   BMC Medical Research Methodology

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

(2016) Jinping Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies

(2016) Jana Podhorna et al.   Alzheimers Research & Therapy

Development of a straightforward and sensitive scale for MCI and early AD clinical trials

(2015) Yifan Huang et al.   Alzheimers & Dementia

Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2

(2015) Clifford R. Jack et al.   Alzheimers & Dementia

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

(2015) Tiia Ngandu et al.   LANCET

New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials

(2015) Nishant Verma et al.   Alzheimers Research & Therapy

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

The Preclinical Alzheimer Cognitive Composite

(2014) Michael C. Donohue et al.   JAMA Neurology

Putting the Alzheimer’s cognitive test to the test I: Traditional psychometric methods

(2012) Jeremy Hobart et al.   Alzheimers & Dementia

The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI

(2012) Jeannine Skinner et al.   Brain Imaging and Behavior

Mixed model of repeated measures versus slope models in Alzheimer’s disease clinical trials

(2012) M. C. Donohue et al.   Journal of Nutrition Health & Aging

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative

(2012) Joshua D. Grill et al.   NEUROBIOLOGY OF AGING

National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

(2011) Thomas J. Montine et al.   ACTA NEUROPATHOLOGICA

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

(2010) S. J. Cano et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Predicting progression of Alzheimer's disease

(2010) Rachelle S Doody et al.   Alzheimers Research & Therapy

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY

Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease

(2008) David S. Knopman   Cognitive and Behavioral Neurology

The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

(2008) Clifford R. Jack et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients

(2008) Jasper D. Sluimer et al.   RADIOLOGY